60 results about "Kynurenine" patented technology

Provided herein are kits, compositions, systems, and methods for treating a subject with a tumor with kynurenine responsive bacteria (e.g., such that the bacteria reduce or eliminate said tumor). In certain embodiments, the kynurenine responsive bacteria comprise one or more nucleic acid sequences comprising: i) a first nucleotide sequence (e.g., not endogenous to said bacteria) encoding a kynurenine transcriptional regulator protein, and ii) a second nucleotide sequence (e.g., not endogenous to said bacteria or overexpressing an endogenous equivalent protein) encoding a kynurenine transporter protein. In particular embodiments, the kynurenine responsive bacteria further comprise at least one of the following: i) a third nucleotide sequence comprising a kynurenine responsive promoter upstream of a plasmid replication gene encoding a plasmid replication protein, ii) a fourth nucleotide sequence comprising a kynurenine responsive promoter upstream of a reporter gene encoding a reporter protein, and iii) a fifth or more nucleotide sequence comprising a kynurenine responsive promoter upstream of a gene essential for bacterial growth, or a gene codes a for therapeutic payload.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

A label-free method for detecting tryptophan and kynurenine in serum based on surface-enhanced Raman scattering (SERS) technology is disclosed, belonging to the field of molecular SERS detection using Raman spectroscopy. The purpose of this invention is to address the problems of expensive equipment, cumbersome operation, and time-consuming analysis in traditional methods for detecting Trp and Kyn molecules, which are difficult to meet the needs of real-time clinical testing, and the current lack of research in the field of direct and simultaneous detection of Trp and Kyn molecules in serum based on label-free SERS technology. Method: 1. Preparation of gold-core tellurium-shell nanoparticles; 2. Preparation of Au@TeNPs SERS substrate using a self-assembly method; 3. SERS detection of tryptophan and kynurenine molecules. This invention, based on the Au@TeNPs SERS substrate, achieves for the first time simultaneous and rapid SERS detection of Trp and Kyn molecules within physiological concentration ranges in serum media. The detection method is rapid, economical, and has significant potential for clinical application.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The application relates to a reagent combination for detecting depression, a manufacturing method, a detection system and application thereof, and belongs to the technical field of instrument detection. The reagent combination for detecting depression comprises a calibrator, a quality control sample and an extraction solution of a to-be-detected compound serving as a biomarker; wherein the to-be-detected compound is at least three kinds selected from 5-hydroxyanthranilic acid, methionine, gamma-aminobutyric acid, 3,4-dihydroxyphenylacetic acid, 2-picolinic acid, quinolinic acid, kynurenine, 5-hydroxytryptamine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, dopamine and norepinephrine. The reagent combination for detecting depression and the detection system can significantly improve the accuracy of diagnosis, are convenient to detect, have good repeatability of detection data, are high in specificity, and are accurate in clinical diagnosis results.

The invention provides a molecularly imprinted material PtCo-MIP for kynurenine detection, a preparation method, application and a product, and belongs to the technical field of analytical chemistry. According to the invention, PtCo alloy is combined with a molecular imprinting technology; wherein the PtCo alloy has more excellent oxidase-like activity compared with Pt nanoparticles, and the molecular imprinting technology solves the problem of insufficient specific detection of a target factor by nano-enzyme by forming a cavity complementary with a kynurenine structure on the surface of the PtCo alloy, so that efficient and safe kynurenine specific recognition is realized, and the detection sensitivity is improved. And the blank of low-cost and high-specificity detection technology in objective diagnosis of depression is filled. The kynurenine detection kit has an extremely wide detection range on kynurenine, and the detection range and the sensitivity are far better than those of an existing commercial kit; meanwhile, the anti-interference capability is excellent, accurate detection can be performed even in a complex matrix, the detection performance is excellent, and an accurate biological basis is provided for early diagnosis of depression.

The present invention relates to a set of molecular markers for assessing preoperative perfusion impairment in acute aortic dissection type A, said serum markers being: L-Kynurenine (Kyn), or L-Tryptophan (Try), or the ratio Kyn / Try (KTR).

A monoclonal antibody, or an antigen-binding fragment thereof, or a synthetic and biotechnological derivative thereof that specifically binds kynurenine (KYN) and acts as a detection marker for inflammation in an individual can be provided.Also, a reliable method and test kit for the detection of inflammation by determining the level of kynurenine in a body fluid, preferably saliva can be provided. Using embodiments of the inventive monoclonal antibody, a tool to determine the level of KYN easily and quickly without the need of any trained person when using saliva as the sample can be provided. This is also beneficial in pediatric medicine and monitoring of various diseases.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The invention relates to a probiotic composite product for improving emotion and a preparation method of the probiotic composite product. The probiotic composite product comprises the following probiotic components: lactobacillus helveticus R0052, lactobacillus plantarum R1012 and bifidobacterium longum R0175. The combination of the three probiotics has a synergistic effect, and can reduce the ratio of kynurenine / tryptophan in a human body and reduce metabolic kynurenine. The probiotic composition can also reduce cortisol and adrenal gland levels, relieve depression and improve mood.

The present invention discloses a metabolic biomarker combination for depression diagnosis, including proline, betaine, alanine, tryptophan, kynurenine, 5-hydroxytryptamine, creatine, succinic acid, taurine, and 2-hydroxybutyric acid. Based on the metabolic biomarker combination, the optimal diagnostic model is screened through a machine learning model algorithm, and a kit for depression diagnosis is constructed.

The invention relates to an Alzheimer's disease biomarker based on intestinal flora metabolites and application of the Alzheimer's disease biomarker. The biomarker comprises any one or a combination of at least two of alpha-ketoglutaric acid, aminocaproic acid, arachidic acid, kynuraminic acid, riboflavin 5-monophosphate, ribonolactone, salicuric acid, serotonin, taurocholic acid-alpha-murine cholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, taurohyodeoxycholic acid and taurine-omega-murine cholic acid. According to the present invention, by detecting the specific metabolite level, the early diagnosis of Alzheimer's disease can be assisted, the non-invasive rapid detection is easily achieved, and the characteristics of timeliness, convenience, high specificity and high sensitivity are provided.

An object of the present invention is to provide a novel composition for suppressing trimethylamine production and / or kynurenine production.SOLUTION: The means for solving the above problems is a composition for inhibiting trimethylamine production and / or kynurenine production, comprising a combination of indigestible dextrin and inulin.SELECTED DRAWING: Figure 1

The invention discloses a lung cancer soft meningeal metastasis marker and application thereof. The marker for the soft meningeal metastasis of the lung cancer comprises one or more of Hydroxyphenylic acid, Betaine, 3-Methoxytyrosine, L-Kyninuine, 1-Methoxyguanosine and 2-Hydroxyphenylethanosine, and whether a subject suffers from the soft meningeal metastasis of the lung cancer or is suspected to suffer from the soft meningeal metastasis of the lung cancer or not can be diagnosed by detecting the level of the marker in a sample of the subject. The invention has a good application prospect in diagnosis of lung cancer soft meningeal metastasis.

This invention discloses urinary metabolic biomarkers for hyperuricemia and their applications, relating to the field of metabolomics technology. It aims to overcome the shortcomings of traditional serum uric acid detection, such as susceptibility to interference, insufficient early warning capabilities, and a lack of sensitive, specific, and non-invasive biomarkers. The urinary metabolic biomarker is at least one of L-kynurenine, indole, and betaine, which can be used to prepare reagents or kits. The assessment system includes a sample analysis unit and a risk assessment model. This invention enables non-invasive and convenient detection of hyperuricemia, accurately captures early metabolic abnormalities, provides reliable risk stratification, and supports clinical auxiliary diagnosis and pathogenesis research.

The invention discloses an application of L-kynurenine in preparation of a medicine for preventing and / or treating skin light injury induced by ultraviolet light. Through a UVA radiation HaCaT cell model, it is proved that L-kynurenine has a remarkable light damage resisting effect and can enhance the mitochondrial function and promote mitochondrial neogenesis, so that the oxidation resistance of cells is improved, and inflammatory response is relieved. Through a UVA combined UVB radiation back unhairing mouse model, it is verified that the hydrogel containing L-kynurenine can effectively repair mouse back skin injury caused by ultraviolet light, the water content and oxidation resistance of skin are improved, and the phenomena of inflammatory response, edema, roughness, erythema or eschar and the like are relieved. Therefore, the invention provides a reference direction for the development, utilization and popularization of the L-kynurenine for preparing the medicine for repairing the skin light injury or the medical beauty product.

The present application relates to the medical examination technical field, specifically to a kind of cancer patient psychological state monitoring method and system, comprising the following steps: detecting serum sample solution tryptophan and kynurenine concentration and operation output measured conversion rate, extract tumor entity diameter and C-reactive protein concentration, input to nonlinear regression model output physiological baseline conversion rate, execute numerical difference operation to obtain metabolic deviation residual value, when exceeding threshold, call segmented linear mapping function to generate psychological stress specific evaluation report.In the present application, by selecting tryptophan and kynurenine conversion rate as monitoring object, introducing tumor diameter and C-reactive protein to construct model to calculate physiological baseline, eliminate physiological metabolic background from measured conversion rate to obtain residual value representing pure psychological factors, realize specific quantitative evaluation of psychological stress state, eliminate masking effect of somatic pathological factors, improve evaluation accuracy and objectivity.

The invention relates to the technical field of medical examination, in particular to a cancer patient psychological state monitoring method and system.The cancer patient psychological state monitoring method comprises the following steps that a serum sample is detected, tryptophan and kynurenine concentrations are solved, the actually-measured conversion rate is calculated and output, and the tumor entity diameter and the C-reactive protein concentration are extracted; inputting the physiological baseline conversion rate into a nonlinear regression model, outputting the physiological baseline conversion rate, executing numerical difference operation to obtain a metabolic deviation residual value, and calling a piecewise linear mapping function to generate a psychological stress specificity evaluation report when the metabolic deviation residual value exceeds a threshold value. According to the method, the conversion rate of tryptophan and kynurenine is selected as a monitoring object, the tumor diameter and C-reactive protein are introduced to construct a model to solve a physiological baseline, a physiological metabolic background is removed from the actually measured conversion rate to obtain a residual value representing pure psychological factors, and specific quantitative evaluation of the psychological stress state is achieved. The body pathological factor masking effect is eliminated, and the evaluation accuracy and objectivity are improved.

A composition comprising an active substance selected from nicotinamide; nicotinic acid; nicotinic acid esters; tryptophan; a tryptophan dipeptide; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); an intermediate in the biosynthesis of NAD or NADP selected from the group consisting of N-formylkynurenine, L-kynurenine, 3-hydroxy-L-kynurenine, 3-hydroxyanthranilate, 2-amino-3-carboxymuconate semialdehyde, quinolinate, nicotinic acid mononucleotide (beta-nicotinate D-ribonucleotide), and nicotinic acid adenine dinucleotide; nicotinamide riboside; nicotinamide mononucleotide; 1-methylnicotinamide (N-methylnicotinamide); or a combination thereof, for use for preventing and / or reducing one or more post-acute symptoms of an infection, wherein the composition is formulated to partly or completely release the active substance(s), preferably nicotinamide, for topical supplementation or efficacy in the lower small intestine and / or the colon, wherein preferably the pathogen is SARS-CoV-2 and / or the post-acute symptoms are PCS

The present invention relates to a biomarker for diagnosing lung cancer and methods for providing artificial intelligence-based information for diagnosing lung cancer, and more particularly to a biomarker for diagnosing lung cancer, comprising kynurenine (KN), lysophosphatidylcholine 16:0 (LPC16), lysophosphatidylcholine 18:0 (LPC18), glutamic acid (Glu), hexanoyl-L-carnitine (HC), octanoyl-L-carnitine (OC), decanoyl-L-carnitine (DC), dodecanoyl-L-carnitine (DDC), myristoyl-L-carnitine (MC) and palmitoyl-L-carnitine (PC), a biomarker composition for diagnosing lung cancer, and a method for providing artificial intelligence-based information for diagnosing lung cancer using the biomarker.As a result of establishing an artificial intelligence-based algorithm model for lung cancer diagnosis using the biomarkers for lung cancer diagnosis selected in the present invention, it was confirmed that the ability to early screen lung cancer is 90.21% sensitivity and 93.03% specificity, which is very high accuracy compared to the existing lung cancer screening method, so the present invention can effectively provide information on lung cancer diagnosis.

Methods and compositions for treating leukemia involving administering a therapeutically effective amount of an inhibitor of indoleamine 2,3 dioxygenase (IDO1). The leukemia may be is acute myeloid leukemia or acute lymphoid leukemia. The inhibitor can be a small molecule such as indiximod, epacadostat, BMS-986205, navoximod, PF-0684003, KHK2455 or LY3381916 or epacadostat. The inhibitor can be used alone or in conjunctions with other chemotherapeutic agents. IDO1 can also be inhibited using a CRISP-CAS system. The inhibitor can be administered orally, intravenously, intramuscularly, topically, arterially, or subcutaneously.

The present invention relates to a method for modulating animal behavior, improving animal welfare and increasing the production of gamma-aminobutyric acid, kynurenine and / or serotonin to improve animal performance using an oligosaccharide preparation.

The invention relates to the field of biological medicine, and discloses a composition targeting a lactobacillus johnsonii-tryptophan metabolic axis and application of the composition. The composition comprises a traditional Chinese medicine extract and lactobacillus johnsonii, the traditional Chinese medicine extract is prepared from radix bupleuri, radix paeoniae alba, fructus aurantii immaturus and honey-fried licorice root. Traditional Chinese medicine extracts of radix bupleuri, radix paeoniae alba, fructus aurantii immaturus and honey-fried licorice root are compounded with lactobacillus johnsonii according to a specific proportion, tryptophan is promoted to be converted into 5-hydroxytryptamine, kynurenine is inhibited from being generated, depression-like behaviors are effectively relieved, the traditional Chinese medicine composition can cooperate with anticancer drugs to remarkably inhibit cancer cell growth, meanwhile, the intestinal barrier function can be improved, the intestinal immunity can be improved, and the curative effect is good. The invention provides a high-safety synergistic treatment scheme with triple effects of tumor inhibition, depression resistance and intestinal tract improvement for patients with liver cancer and depression.

The invention relates to a kit for evaluating the risk of PD-1 immune drug-related adverse reactions (irAE). The kit comprises a component for detecting a specific biomarker group, and the biomarker group comprises a protein marker selected from the group consisting of ATP6V1G1, GOT2, CD63 and CHCHD4, and / or a metabolite marker selected from the group consisting of kynurenine, tryptophan and phosphatidylcholine PC (17: 117: 1) and PC (17: 226: 7). According to the kit, by analyzing biomarker signals detected by the components of the kit, objective indexes can be provided for evaluating the risk of irAE of a patient. The kit disclosed by the invention is suitable for detecting a biological sample in an in-vitro environment and provides information support for clinical decision-making.

The present invention relates to methods for using oligosaccharide preparations to modulate animal behavior, improve animal welfare, and increase the production of gamma-aminobutyric acid, kynurenine and / or serotonin to improve animal performance.

The present invention relates to a biomarker for diagnosing lung cancer and methods for providing artificial intelligence-based information for diagnosing lung cancer, and more particularly to a biomarker for diagnosing lung cancer, comprising kynurenine (KN), lysophosphatidylcholine 16:0 (LPC16), lysophosphatidylcholine 18:0 (LPC18), glutamic acid (Glu), hexanoyl-L-carnitine (HC), octanoyl-L-carnitine (OC), decanoyl-L-carnitine (DC), dodecanoyl-L-carnitine (DDC), myristoyl-L-carnitine (MC) and palmitoyl-L-carnitine (PC), a biomarker composition for diagnosing lung cancer, and a method for providing artificial intelligence-based information for diagnosing lung cancer using the biomarker. As a result of establishing an artificial intelligence-based algorithm model for lung cancer diagnosis using the biomarkers for lung cancer diagnosis selected in the present invention, it was confirmed that the ability to early screen lung cancer is 90.21% sensitivity and 93.03% specificity, which is very high accuracy compared to the existing lung cancer screening method, so the present invention can effectively provide information on lung cancer diagnosis.

The purpose of the invention is to solve the above-mentioned problems existing in the prior art (mainly for the adverse reactions of using photothermal therapy alone and immunotherapy alone), by constructing a supramolecular photothermal agent, and proposing a compound for photothermal and immune combined therapy and its pharmaceutical composition. This type of compound can self-assemble into a micro-nano structure in water, and through the "passive targeting" of the EPR effect, the photothermal agent is enriched in the tumor tissue. When the photothermal agent emits light under 808nm laser irradiation, it releases heat to achieve integrated diagnosis and treatment, with the advantages of high photothermal conversion efficiency, excellent photothermal stability and easy degradation and high safety. At the same time, because the immune checkpoint inhibitor NLG919 used in this project in the tumor can inhibit IDO-1 activity, reverse the immunosuppressive microenvironment, activate the anti-tumor cascade immune effect, and induce cancer cell immunogenic cell death (ICD), and through NLG919-mediated IDO1 inhibition, it effectively delays the degradation of tryptophan to the immunosuppressant kynurenine, thereby promoting the decrease in the level of regulatory T cells and the increase in the level of effector T cells, achieving the therapeutic effect of immune killing.

The invention discloses a metabolic biomarker combination for diagnosing depression. The metabolic biomarker combination comprises proline, betaine, alanine, tryptophan, kynurenine, 5-hydroxytryptamine, creatine, succinic acid, taurine and 2-hydroxybutyric acid. Based on a metabolic biomarker combination, an optimal diagnosis model is screened through a machine learning model algorithm, and the kit for depression diagnosis is constructed.

The invention relates to an application of type I classical dendritic cells in preparation of drugs for treating drug-induced hepatic failure. The application focuses on the cell subtype cDC1 which is very important for balancing the immune homeostasis in the liver, the reduction of cDC1 subgroups is proved in the liver tissues of AILF patients and mice, and the feedback tolerance type cDC1 is fully proved to be capable of remarkably relieving liver injury and inflammatory cell infiltration in the liver tissues on the in-vivo level of an AILF mouse model, promoting liver regeneration and repair, and improving the liver injury and the inflammatory cell infiltration in the liver tissues. The process is related to the mechanism that P300 activates IDO1 gene transcription through mediating H3K27ac modification so as to promote the immune tolerance phenotype of cDC1, the tolerance type cDC1 further decomposes tryptophan and secretes kynurenine through high-expression IDO1, Tregs differentiation and functions are induced, the in-liver immune homeostasis is maintained, liver cell proliferation and damage repair are promoted by secreting immunosuppressive factors, and the immune tolerance phenotype of cDC1 is promoted. And an important early-stage experimental basis is provided for research and development of new drugs based on the targets.